Know the Other "Omics": Exploring Drug and Diagnostics Development Through Proteomics
Decision Resources
March 30, 2009 25 Pages - SKU: DECR2199610
|
|
Introduction
Genomics has paved the way for its cousin, proteomics, to secure its share of the "omics" hype. Researchers
look to proteomics to deliver on the promise to assess the viability of drug targets for monitoring disease progression,
optimizing disease management, and diagnosing diseases with more precision. While many challenges
are inherent, given the complexities of protein-centric science, technological improvements in the fi eld have
resulted in important gains for biopharma.
Get the Answers You Need to Shape Your Strategy
- Partnering in proteomics is slowing despite the potential of the associated technologies to revolutionize drug discovery, diagnostics development, and disease management. What problems are inherent in protein biomarker research? What solutions have been developed to help overcome the obstacles?
- Navigating the proteomics research process of preparation, separation, identifi cation, and validation is complex. Which step is most critical upstream to improve results downstream?
- Proteomics technologies give rise to a select set of protein biomarkers. What are the differences between biomarkers for drug discovery and those for diagnostics development?
Scope
- Proteomics technologies: 2DGE, MS, MALDI, SELDI, TOF, bioinformatics.
- Proteomics research process: Innovative methods of sample preparation, separation and capture, identifi cation and analysis, and clinical validation.
- Companies with valuable insight into protein biomarker discovery: 20/20GeneSystems, Caprion Proteomics, NextGen BioSciences, Oxford GlycoSciences.
- Outlook: Proteomics is approaching the long-awaited recognition that it has the potential to deserve. Novel tools now in use will improve greatly owing to collaborative initiatives that will stimulate innovation in protein research processes.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
Additional InformationCompanies and Organizations
- 20/20 GeneSystems
- Abbott Labs
- Accacia International
- Agilent
- Allele Biotechnology & Pharmaceuticals
- Amersham (now GE Healthcare)
- Argonne National Laboratory
- AxCell Biosciences
- Battelle Pacifi c Northwest Laboratories
- BD Biosciences
- Bio-Rad Laboratories
- Biosite
- BioVision
- Bristol-Myers Squibb
- Broad Institute of MIT and Harvard, Proteomic
Platform and Cancer Program
- Bruker Daltonics
- Buck Institute for Age Research
- California Pacifi c Medical Center
- Caprion Proteomics
- Ciphergen (now Bio-Rad Laboratories)
- College of William and Mary
- Dade Behring
- DakoCytomation
- Developmental Studies Hybridoma Bank at the
University of Iowa
- Discovery Park at Purdue University
- Emory University
- Epitome
- European Bioinformatics Institute
- Fred Hutchinson Cancer Research Center
- Genomic Solutions
- GenTel Biosciences
- Harvard Institute of Proteomics
- Harvard University and its affi liated hospitals
(including Dana-Farber Cancer Institute and
Massachusetts General Hospital)
- Hoosier Oncology Group
- Human Protein Atlas (KTH—Royal Institute of
Technology; Stockholm, Sweden)
- Hybrigenics
- Indiana University
- Indiana University—Purdue University Indianapolis
- Indiana University School of Medicine
- Institute for Systems Biology
- Invitrogen
- Johnson & Johnson
- Large Scale Biology
- Lawrence Berkeley National Laboratory
- Massachusetts Institute of Technology
- Matritech
- Memorial Sloan-Kettering Cancer Center
- Meso Scale Diagnostics
- Michigan State University
- Molecular Staging
- Monarch Life Sciences
- National Cancer Institute, Center for Cancer Research Tissue Array Program
- National Cancer Institute, Frederick Advanced Technology Program
- National Institute of Standards and Technology
- New York University Medical Center
- NextGen Sciences
- Northeastern University
- Novartis
- Oxford GlycoSciences
- Pfi zer
- Plasma Proteome Institute
- Predictive Physiology and Medicine
- Procter & Gamble
- Purdue University
- Quadraspec
- Roche Diagnostics
- Rules-Based Medicine
- Seattle Children’s Hospital and Regional Medical Center
- Sequenom
- Sigma-Aldrich
- University of British Columbia
- University of California, Los Angeles
- University of California, San Francisco
- University of Colorado at Boulder
- University of Houston
- University of Maryland, College Park
- University of Michigan
- University of Texas M.D. Anderson Cancer Center
- University of Victoria Genome British Columbia Proteomics Centre
- University of Virginia
- University of Washington
- Vanderbilt-Ingram Cancer Center
- Vanderbilt University Medical Center
- Zyomix
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Inherent Challenges in Researching Proteins
- Proving the Value of Proteomics
- Understanding the Proteomics Approach
- Sample Preparation
- Separation and Capture, Analysis and Identifi cation
- Planning Ahead for Clinical Validation
- Recent Perspectives on Proteomic Technologies
- Two-Dimensional Gel Electrophoresis
- Mass Spectrometry
- Bioinformatics Tools
- Biopharma Players in the Protein Research Arena
- Caprion Proteomics
- NextGen Sciences
- Power3 Medical Products
- Notable Initiatives in Proteomics
- Clinical Proteomic Technologies for Cancer
- Spectrum Expert Commentary
- Revitalizing Personalized Medicine Through Proteomics
- Improvements in Proteomics
- Protein Assay Platforms
- Spectrum Expert Commentary (cont.)
- Assay Availability
- At a Major Turning Point
- About the Author
- Human Plasma Proteome Project
- Outlook
- Overcoming Key Challenges
- Building Capacity Through Collaboration
- Tables
- 1. Select Diagnostic Tests Based on Protein Biomarkers
- 2. Advantages and Disadvantages of 2DGE and MS Technologies
- 3. Select Protein Sequencing Databases
- 4. Select Proteomics Companies of Interest
- 5. Participants in the Clinical Proteomic Technologies for Cancer Initiative
- 6. Pharmaceutical and Diagnostics Company Sponsors of the Human Plasma Proteome Project
- Figures
- 1. FDA Approval of NMEs Compared with R&D Spending, 2000-2008
- 2. Sensitivities and Specifi cities of Select FDA-Approved Protein Biomarkers
- 3. Proteomics Research Process
- 4. Comparison of Protein Sample Sources
- 5. Number of Alliances Involving Proteomics, 2001-2008
- Expert Commentary
- Revitalizing Personalized Medicine Through Proteomics.
- M. Walid Qoronfl eh, Ph.D., M.B.A.,
- Vice President of Business Development at NextGen Sciences
Share this report
Other tasks Related Markets Research & Development Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
